Intact urothelial cells isolated from bladders of untreated inbred NZO/BIGd or NZC/BIGd mice and NZR/Gd rats activated dimethyl, diethyl, dipropyl, and dibutyl nitrosamines in a liquid culture mutagenesis fluctuation assay using Salmonella typhimurium TA100 as target organism. Rat and mouse urothelial cells were highly effective at 1.5 X 10(5) cells/ml, in O2 gas phase, and no cofactors were required. Relative mutagenic activities were estimated at equitoxic (LD50) concentrations of the 4 nitrosamines. Nitrosamines with odd-carbon chain substitutents were more active than the C-even compounds. Although dibutylnitrosamine is a powerful bladder carcinogen in both rats and mice while the other 3 compounds very rarely cause bladder tumours, the most active promutagens were dipropyl and dimethyl, followed by diethyl and dibutyl nitrosamines. None were active in absence of urothelial cells. Mouse bladder cells were more active than those from NZR rats. There were sex differences in the mice with NZC males and NZO females predominating, but in NZR rats urothelial cells from male and female animals were equally active. These dialkylnitrosamines are widely distributed in the environment, and our results indicate that direct mutagenic activation in the urothelium could be one factor contributing to the incidence of bladder cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0165-1218(85)90054-0DOI Listing

Publication Analysis

Top Keywords

urothelial cells
20
mutagenic activation
8
intact urothelial
8
dimethyl diethyl
8
dibutyl nitrosamines
8
nzr rats
8
cells
6
urothelial
5
active
5
activation dialkylnitrosamines
4

Similar Publications

Limited research into the tumor immune microenvironment (TIME) for bladder urothelial carcinoma (BUC), particularly the neglect of the intratumoral microbiota, has hindered the development of immunotherapies targeting BUC. Here, we collect 401 patients with BUC with host transcriptome samples and matched tumor microbiome samples from The Cancer Genome Atlas database. Besides, two independent BUC cohorts receiving immunotherapy were obtained.

View Article and Find Full Text PDF

Background: The Nectin-4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous expression of this protein in UC. There is limited data available regarding expression of Nectin-4 by immunohistochemistry in prostate cancer, but this is of interest as a substantial number of UC patients likely to receive EV have concomitant prostate cancer.

Methods: Nectin-4 protein expression was evaluated by immunohistochemistry in tissue microarrays encompassing a cohort of 302 prostatic adenocarcinomas spanning Grade Groups 1-5.

View Article and Find Full Text PDF

Autophagy is a common cellular degradation and recycling process that plays crucial roles in the development, progression, immune regulation, and prognosis of various cancers. However, a systematic assessment of the autophagy-related genes (ATGs) across cancer types is deficient. Here, a transcriptome-based pan-cancer analysis of autophagy with potential implications in prognosis and therapy response was performed.

View Article and Find Full Text PDF

Background: Several studies indicate that smoking is one of the major risk factors for bladder cancer. Nicotine and its metabolites, the main components of tobacco, have been found to be strongly linked to the occurrence and progression of bladder cancer. However, the function of nicotine metabolism-related genes (NRGs) in bladder urothelial carcinoma (BLCA) are still unclear.

View Article and Find Full Text PDF

Background And Aim: Growth factor receptor-bound protein 7 (GRB7) belongs to a group of adaptor proteins characterized by their conserved multidomain structure. These proteins are involved in cellular signaling pathways that regulate cell growth, proliferation, and differentiation. Alterations in GRB7 expression have been linked to multiple human cancers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!